From Coverage to Care: Medicaid Expansion’s Impact on Breast Cancer Outcomes

Health policy remains a major factor in determining the availability of preventive care, diagnostics, and treatment across the oncology spectrum. In breast cancer, where early detection and prompt treatment greatly increase the chance of survival, insurance coverage is a key factor influencing the results.

Data from a recent study indicate that the expansion of Medicaid following the Affordable Care Act (ACA) has led to significant decreases in breast cancer deaths, especially among low-income groups. Findings from a large national study and related assessments demonstrate that expanding insurance coverage can lead to greater survival over time, while also identifying deeply embedded disparities that need to be addressed.^1-3

Data from a major study published in JAMA Network Open analyzed over 1.5 million women diagnosed with breast cancer from 2004 to 2019 and studied mortality outcomes in states that expanded Medicaid and those that did not.² The researchers revealed that expansion decreased breast cancer–specific mortality rates, especially in younger patients and those from socioeconomically disadvantaged communities.

The authors emphasized the dual nature of these findings, writing, “These findings highlight population-wide benefits while underscoring persistent inequities; policies that pair coverage expansion with targeted efforts to improve timely diagnosis, treatment access, and adherence may be needed to close these gaps.”² This statement underscores that although insurance expansion improves outcomes overall, coverage alone may be insufficient to eliminate longstanding structural barriers.

In an accompanying commentary, Meghan Maceyko, MD; and Oluwadamilola Fayanju, MD, MA, MPHS, of the Perelman School of Medicine at the University of Pennsylvania noted that the results aligned with prior research data, “but [this study] is notable for its large cohort of more than 1.5 million women and a follow-up period of more than 10 years, highlighting the durable impact of Medicaid expansion on breast cancer mortality.”¹ They also cautioned that despite the study’s rigorous design, “residual and unmeasured confounding remained possible,” reinforcing the need for cautious interpretation.

Mechanisms Driving Improved Survival

Several pathways likely explain how Medicaid expansion contributes to reduced breast cancer mortality. Having an insurance plan helps patients access timely screening mammograms, diagnostic imaging, and biopsy services, making it easier to obtain an early diagnosis. Identification at an early stage has been shown to lead to a higher cure rate and more available treatment options.³

Cancer insurance coverage expands patients’ access to multidisciplinary oncology care involving surgery, radiation, systemic therapy, and supportive services. Individuals on Medicaid are more likely to start treatment sooner and follow their treatment plans more closely than those without any insurance. Regular access to follow-up and survivorship care plays a vital role in securing favorable long-term health results.

Persistent Disparities and Equity Challenges

Despite overall improvements, a component of the study showed that Black women and other individuals from historically marginalized communities had an even lower reduction in mortality than White patients.² The results from this study align with the previously established evidence that racial and socioeconomic disparities persist even among insured populations.

Factors such as the geographic location of cancer centers, the lack of public transport, workforce shortages, and implicit bias may not help insurance expansion have a significant impact.³ Additionally, differences in Medicaid reimbursement rates and provider participation can affect the availability of high-quality oncology services.

An analysis by MedPage Today highlighted that expansion enhances coverage stability; however, in regions with limited oncology infrastructure, “coverage does not automatically equate to equal care.” Closing these gaps requires coordinated policy, health systems, and community-level strategies.¹

Implications for Pharmacists and Oncology Care Teams

Pharmacists have an important role in helping patients take full advantage of expanded coverage. As accessible health care professionals, pharmacists support medication access, adherence, and patient education, which are closely tied to survival outcomes. Ensuring the timely initiation of endocrine therapy, chemotherapy, and supportive medications is essential, particularly for patients who have newly gained insurance coverage.

Pharmacists can also help patients understand Medicaid formularies, prior authorization, and financial assistance programs. These services help minimize delays and interruptions in treatment, which mainly affect low-income patients. Additionally, oncology pharmacists help monitor adverse effects, promote patients’ adherence to treatment, and support patients in continuing therapies as per guidelines.⁴

REFERENCES

1. Bassett M. Medicaid expansion linked to lower mortality in breast cancer. MedPage Today. January 27, 2026. Accessed February 17, 2026. https://www.medpagetoday.com/hematologyoncology/breastcancer/119612

2. Akinyemi O, Oyebanji O, Fasokun M, et al. Medicaid expansion and overall mortality among women with breast cancer. JAMA Netw Open. 2026;9(1):e2554512. doi:10.1001/jamanetworkopen.2025.54512

3. Schafer EJ, Johnson CJ, Moraes FY, Han X, Zhao J, Jemal A. Association between Medicaid expansion and 5-year survival among individuals diagnosed with cancer. Cancer Discov. 2025;15(12):2431-2436. doi:10.1158/2159-8290.CD-25-1244

4. Holle LM, Segal EM, Jeffers KD. The expanding role of the oncology pharmacist. Pharmacy (Basel). 2020;8(3):130. doi:10.3390/pharmacy8030130